Key Developments: Cesca Therapeutics Inc (KOOL.PH)

KOOL.PH on Philadelphia Stock Exchange

3 Mar 2015
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Cesca Therapeutics Inc announces filing of U.S. Pivotal IDE Application for No-Option Critical Limb Ischemia
Thursday, 20 Nov 2014 06:00am EST 

Cesca Therapeutics Inc:Says it has submitted an investigational device exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for a pivotal multicenter study of its SurgWerks-CLI and VXP System ("SURGWERKS-CLI") for treating advanced stages of no-option lower limb critical limb ischemia.Says the IDE application is the result of two prior positive pilot and feasibility studies conducted in Italy and India, respectively, and collaborative pre-IDE feedback from the U.S. FDA.Says CLIRST III study is a double blinded randomized controlled trial to evaluate the safety and efficacy of the SURGWERKS-CLI and VXP System in CLI patients with non-healing foot ulcers who have no further surgical options, and will be compared against a placebo control of the same population.Says the primary endpoint is major amputation free survival at 12 months following enrollment. The study will be conducted in about 60 sites with up to 3 sites in India.  Full Article

Cesca Therapeutics Inc announces Robin C. Stracey as interim CEO
Wednesday, 29 Oct 2014 09:00am EDT 

Cesca Therapeutics Inc:Intends to embark on a nationwide search for a new Chief Executive Officer. Robin C. Stracey, currently a member of the company's board of directors, will serve as interim CEO pending the new hire.  Full Article

Cesca Therapeutics and Fortis Healthcare announce master collaboration agreement
Tuesday, 5 Aug 2014 05:59am EDT 

Cesca Therapeutics Inc and Fortis Healthcare Ltd:Says a master collaboration agreement that extends their important existing relationship.Agreement affirms Cesca's cellular therapy and cord blood bank at the Fortis Hospital Memorial Research Institute (FMRI) in Gurgaon, renews the cord blood banking collaboration and launches the stem cell therapy services for hematological diseases across the Fortis network.  Full Article

Cesca Therapeutics Inc announces pricing of public offering of common stock
Friday, 13 Jun 2014 08:29am EDT 

Cesca Therapeutics Inc:Says the pricing of an underwritten public offering of 7,530,000 Units, consisting of an aggregate of 7,530,000 shares of the Company's common stock and warrants to purchase 2,259,000 shares of the Company's common stock, at a price of $1.50 per Unit.Each warrant entitles the holder to purchase 0.30 of a share of common stock.Warrants will be exercisable immediately upon issuance at an exercise price of $1.55 per share and will expire five years from the date of issuance.Shares of common stock and warrants comprising the Units are immediately separable.All of the Units in the offering are being sold by Cesca.Says gross proceeds to Cesca from this offering are expected to be about $11.3 mln, excluding any future proceeds from the potential exercise of the warrants and before deducting underwriting discounts and commissions and other estimated offering expenses payable by Cesca.Says offering is expected to close on or about June 18 subject to the satisfaction of customary closing conditions.Maxim Group LLC is acting as sole book-running manager and H.C. Wainwright & Co., LLC is acting as a co-manager for the offering.  Full Article

Cesca Therapeutics announces proposed public offering
Thursday, 12 Jun 2014 04:32pm EDT 

Cesca Therapeutics Inc:Intends to offer Units consisting of its shares of common stock and warrants to purchase shares of common stock in an underwritten public offering.Shares of common stock and warrants comprising the units are immediately separable.All of the Units in the offering are being sold by Cesca.Maxim Group LLC is acting as sole book-running manager for the offering.  Full Article

Cesca Therapeutics Inc and Cook Medical enter supply agreement for phase 1b clinical trial
Monday, 24 Feb 2014 09:00am EST 

Cesca Therapeutics Inc:Says has entered a supply agreement with Cook Medical.Under the terms of the agreement, Cook Medical has been chosen as the supplier for select delivery device products for the AMIRST (Acute Myocardial Infarction Rapid Stem cell Therapy) Phase Ib trial set to begin later this calendar year.The clinical trial is for targeted marketing approval in the United States, European Union Community and India.  Full Article

Cesca Therapeutics Inc, Formerly ThermoGenesis Corp, closes merger with Totipotentrx Corp and changes name
Wednesday, 19 Feb 2014 07:30am EST 

Cesca Therapeutics Inc (f/n/a ThermoGenesis Corp):Consummats the merger with TotipotentRX Corporation for about 12,490,800 shares of the company's common stock, as contemplated by the previously announced agreement and plan of reorganization.Further, to reflect the surviving company's combined strength, the Company changed its name to Cesca Therapeutics Inc.Cesca stands for Clinical Excellence in Stem Cell Applications.expects to begin trading on Nasdaq as Cesca Therapeutics Inc. on Feb. 20, 2014.Will continue to trade under the Nasdaq ticker symbol KOOL.  Full Article

ThermoGenesis Corp raises $6.67 mln in private placement financing
Monday, 27 Jan 2014 09:00am EST 

ThermoGenesis Corp:Enters into definitive agreements with institutional investors in connection with a private placement of common stock and warrants to purchase common stock.Says upon the closing of this financing.Says it will receive gross proceeds of about $6.67 mln resulting from the issuance and sale of about 3.33 mln shares of common stock at a price per share of $2.00.Says purchasers will also receive warrants to purchase up to approximately 1.66 million shares of common stock at an exercise price of $2.81 per share.Says warrants are non-exercisable for six months after the closing of the financing and have a term of 5 years.Intends to use the aggregate net proceeds of the financing primarily for general corporate purposes, as well as for the continued advancement of its pipeline of clinical trials within the cardiovascular and orthopedic markets.Says Maxim Group LLC acted as sole placement agent for the financing.  Full Article

ThermoGenesis Corp signs direct supply agreement with Cord Blood Registry
Wednesday, 8 Jan 2014 09:00am EST 

ThermoGenesis Corp:Says the signing of a five-year agreement to supply Cord Blood Registry (CBR), with ThermoGenesis' AutoXpress System (AXP) cord blood processing system and disposables.  Full Article

ThermoGenesis Corp And TotipotentRx Corporation Announce Definitive Merger Agreement
Tuesday, 16 Jul 2013 07:00am EDT 

ThermoGenesis Corp and TotipotentRx Corporation announced that they have entered into a definitive merger agreement. The combined company is expected to become one of the first fully integrated regenerative medicine companies, developing clinically validated, commercially scalable, point-of-care cell therapies for therapeutic markets, including orthopedic, cardiovascular and neurologic indications. Under terms of the agreement, ThermoGenesis will issue approximately 12,491,000 shares of its common stock to TotiRx which equates to a value of approximately $18.6 million, based on ThermoGenesis' closing stock price of $1.49 on July 15, 2013. The merger agreement has been unanimously approved by the board of directors of each company. The transaction is expected to close in the fourth quarter of calendar year 2013 and is subject to customary closing conditions, certain financial conditions, regulatory approvals and approval by the shareholders of ThermoGenesis and TotiRx. The combined company is expected to be named Cesca Therapeutics (Clinical Excellence in Stem Cell Applications) and will continue to trade on NASDAQ under the ticker symbol KOOL. Roth Capital Partners acted as financial advisor to ThermoGenesis and rendered a Fairness Opinion to its Board of Directors in this transaction and Weintraub Tobin Chediak Coleman Grodin Law Corporation acted as legal counsel to ThermoGenesis.  Full Article

Search Stocks